MAPT and Alzheimer disease: Common biomarkers include cerebrospinal fluid (CSF) tau and amyloid-beta levels, which are primarily used in Alzheimer’s disease (AD), and the neurofilament light chain (NfL), a marker for neuronal damage across various neurodegenerative conditions.